Artificial intelligence is moving from buzzword to working tool across the pharmaceutical industry, with companies betting it can speed up how new drugs are discovered, tested, and brought to patients.
Eli Lilly is one of the clearest examples. According to a Seeking Alpha analysis, the company is using its strong cash flow to build an "AI-native" drug discovery and manufacturing platform — and the author argues this, rather than its well-known weight-loss franchise, may be the real long-term upside for the stock, which they rate a Buy.
Lilly is also reaching outside its own walls. Pharmacy Times reports on a collaboration between Lilly and Chai Discovery aimed at advancing AI-driven development of biologics, the complex protein-based medicines that are harder to design than traditional small-molecule drugs.
The trend extends to smaller players. According to drugdiscoverytrends.com, a startup called Remepy — which pairs drugs with AI-driven apps — has cleared a Phase IIa trial in Parkinson's disease, an early sign that combining medication with software may show clinical results.
Diagnostics are part of the shift too. A separate Seeking Alpha piece points to Tempus AI, noting recent FDA approval for a tumor-only indication of its xT CDx test and an upcoming xH assay that the author says broadens the company's clinical reach; they rate the stock a Strong Buy.
Why it matters: drug development is famously slow and expensive, so even incremental gains from AI — in discovery, biologics design, or diagnostics — could change how quickly and cheaply new treatments reach the people who need them.